ELIQUIS TABLET 5MG

Riik: Singapur

keel: inglise

Allikas: HSA (Health Sciences Authority)

Toimeaine:

Apixaban

Saadav alates:

PFIZER PRIVATE LIMITED

ATC kood:

B01AF02

Annus:

5mg

Ravimvorm:

TABLET, FILM COATED

Koostis:

Apixaban 5mg

Manustamisviis:

ORAL

Retsepti tüüp:

Prescription Only

Valmistatud:

Bristol-Myers Squibb Manufacturing Company Unlimited Company

Volitamisolek:

ACTIVE

Loa andmise kuupäev:

2013-09-11

Infovoldik

ELIQUIS 5 MG FILM-COATED TABLETS
Table of Content
_Please click on either of the following links to access the required
information: _
PRESCRIBING INFORMATION
PATIENT INFORMATION LEAFLET
Page 1 of 25
1. NAME OF THE MEDICINAL PRODUCT
ELIQUIS 5 mg film-coated tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 5 mg apixaban.
Excipient(s) with known effect
Each 5 mg film-coated tablet contains 102.9 mg lactose (see section
4.4).
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Film-coated tablet
Pink, oval shaped, biconvex film-coated tablets with “894”
debossed on one side and “5” on the other
side.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Prevention of stroke and systemic embolism in adult patients with
non-valvular atrial fibrillation
(NVAF), with one or more risk factors, such as prior stroke or
transient ischaemic attack (TIA); age
≥75 years; hypertension; diabetes mellitus; symptomatic heart
failure (NYHA Class ≥II).
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE),
and prevention of recurrent
DVT and PE in adults (see section 4.4 for haemodynamically unstable PE
patients).
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Prevention of stroke and systemic embolism in patients with
non-valvular atrial fibrillation (NVAF)_
The recommended dose of apixaban is 5 mg taken orally twice daily.
_Dose reduction_
The recommended dose of apixaban is 2.5 mg taken orally twice daily in
patients with NVAF and at
least two of the following characteristics: age ≥80 years, body
weight ≤60 kg, or serum creatinine
≥1.5 mg/dL (133 micromole/L).
Therapy should be continued long term.
_Treatment of DVT, treatment of PE and prevention of recurrent DVT and
PE (VTEt)_
The recommended dose of apixaban for the treatment of acute DVT and
treatment of PE is 10 mg
taken orally twice daily for the first 7 days followed by 5 mg taken
orally twice daily. As per available
medical guidelines, short duration of treatment (at least 3 months

Toote omadused

1. NAME OF THE MEDICINAL PRODUCT
ELIQUIS 5 mg film-coated tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 5 mg apixaban.
Excipient(s) with known effect
Each 5 mg film-coated tablet contains 102.9 mg lactose (see section
4.4).
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Film-coated tablet
Pink, oval shaped, biconvex film-coated tablets with “894”
debossed on one side and “5” on the other
side.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Prevention of stroke and systemic embolism in adult patients with
non-valvular atrial fibrillation
(NVAF), with one or more risk factors, such as prior stroke or
transient ischaemic attack (TIA); age
≥75 years; hypertension; diabetes mellitus; symptomatic heart
failure (NYHA Class ≥II).
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE),
and prevention of recurrent
DVT and PE in adults (see section 4.4 for haemodynamically unstable PE
patients).
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Prevention of stroke and systemic embolism in patients with
non-valvular atrial fibrillation (NVAF)_
The recommended dose of apixaban is 5 mg taken orally twice daily.
_Dose reduction_
The recommended dose of apixaban is 2.5 mg taken orally twice daily in
patients with NVAF and at
least two of the following characteristics: age ≥80 years, body
weight ≤60 kg, or serum creatinine
≥1.5 mg/dL (133 micromole/L).
Therapy should be continued long term.
_Treatment of DVT, treatment of PE and prevention of recurrent DVT and
PE (VTEt)_
The recommended dose of apixaban for the treatment of acute DVT and
treatment of PE is 10 mg
taken orally twice daily for the first 7 days followed by 5 mg taken
orally twice daily. As per available
medical guidelines, short duration of treatment (at least 3 months)
should be based on transient risk
factors (e.g., recent surgery, trauma, immobilisation).
The recommended dose of apixaban for the prevention of recurrent DVT
and PE is 2.5 mg taken
orally twice dai